Literature DB >> 29787481

Sex hormone levels and risk of primary open-angle glaucoma in postmenopausal women.

Jae Hee Kang1, Bernard A Rosner1,2, Janey L Wiggs3, Louis R Pasquale1,3.   

Abstract

OBJECTIVE: We evaluated the relation of prediagnostic sex hormone levels in postmenopausal women with primary open-angle glaucoma (POAG) and intraocular pressure (IOP).
METHODS: Among postmenopausal participants of the Nurses' Health Study, POAG cases (n = 189; diagnosed 1990-2008) and controls (n = 189) were matched on age, fasting status, and postmenopausal hormone use at blood draw (1989-1990). Plasma concentrations of estrone sulfate, estradiol, testosterone, sex hormone binding globulin, and dehydroepiandrosterone sulfate were assessed. The primary outcome was POAG; in secondary analyses, among cases only, we evaluated maximum untreated IOP at diagnosis. Multivariable-adjusted logistic/multiple linear regression models were used to evaluate tertiles (Ts) of biomarker levels and the two outcomes, adjusting for various potential confounders.
RESULTS: We observed no significant associations of estrone, estradiol, sex hormone binding globulin, or dehydroepiandrosterone sulfate with POAG risk or with maximum IOP at glaucoma diagnosis among cases. Suggestive significant associations were observed with highest testosterone and POAG risk (T3 vs T1 multivariable-adjusted odds ratio 1.84; 95% confidence interval 1.02, 3.33; P trend 0.10). Similarly, for maximum IOP at diagnosis among cases only (mean 8 years after blood draw), higher testosterone was significantly associated with higher IOP (multivariable-adjusted difference in IOP T3 vs T1 2.17 mm Hg; 95% confidence interval 0.34, 3.99; P trend 0.02).
CONCLUSIONS: Overall, plasma sex hormone levels in postmenopausal women were not associated with POAG risk; however, a trend of higher testosterone levels being associated with higher POAG risk and higher IOP at diagnosis was observed and needs confirmation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29787481      PMCID: PMC6136969          DOI: 10.1097/GME.0000000000001120

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  56 in total

1.  Presence of oestrogen receptor type beta in human retina.

Authors:  C Munaut; V Lambert; A Noël; F Frankenne; M Deprez; J M Foidart; J M Rakic
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

2.  Insulin Resistance Is a Risk Factor for Increased Intraocular Pressure: The Hisayama Study.

Authors:  Kohta Fujiwara; Miho Yasuda; Toshiharu Ninomiya; Jun Hata; Sawako Hashimoto; Takeshi Yoshitomi; Yutaka Kiyohara; Tatsuro Ishibashi
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

Review 3.  The intracrine sex steroid biosynthesis pathways.

Authors:  Van Luu-The; Fernand Labrie
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

4.  Cornea in PCOS patients as a possible target of IGF-1 action and insulin resistance.

Authors:  Ayse Gul Kebapcilar; Mehmet Gurkan Tatar; Suleyman Hilmi Ipekci; Gulsum Gonulalan; Huseyin Korkmaz; Suleyman Baldane; Cetin Celik
Journal:  Arch Gynecol Obstet       Date:  2014-07-15       Impact factor: 2.344

5.  [Effect of hormone replacement therapy on postmenopausal ocular function].

Authors:  C Sorrentino; P Affinito; F Mattace Raso; M Loffredo; P Merlino; A Loffredo; S Palomba; C Nappi
Journal:  Minerva Ginecol       Date:  1998 Jan-Feb

6.  Influence of norethynodrel with mestranol on intraocular pressure in glaucoma. II. A controlled double-blind study.

Authors:  E J Meyer; C R Roberts; H M Leibowitz; B McGowan; R E Houle
Journal:  Arch Ophthalmol       Date:  1966-06

7.  Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study.

Authors:  G A Laughlin; E Barrett-Connor; D Kritz-Silverstein; D von Mühlen
Journal:  J Clin Endocrinol Metab       Date:  2000-02       Impact factor: 5.958

8.  The effects of menopause and hormone replacement therapy on quality and quantity of tear, intraocular pressure and ocular blood flow.

Authors:  Ozgül Altintaş; Yusuf Caglar; Nurşen Yüksel; Ali Demirci; Levent Karabaş
Journal:  Ophthalmologica       Date:  2004 Mar-Apr       Impact factor: 3.250

9.  Vascular reactivity is impaired in genetic females taking high-dose androgens.

Authors:  R J McCredie; J A McCrohon; L Turner; K A Griffiths; D J Handelsman; D S Celermajer
Journal:  J Am Coll Cardiol       Date:  1998-11       Impact factor: 24.094

10.  Attributes of female reproductive aging and their relation to primary open-angle glaucoma: a prospective study.

Authors:  Louis R Pasquale; Bernard A Rosner; Susan E Hankinson; Jae Hee Kang
Journal:  J Glaucoma       Date:  2007 Oct-Nov       Impact factor: 2.503

View more
  4 in total

1.  Effects of testosterone on intraocular pressure, thicknesses of retinal nerve fiber layer, ganglion cell complex, macula and on ocular blood flow in female-to-male transgender persons.

Authors:  Oksan Alpogan; Emin Erhan Donmez; Ayşe Özlem Balık; Fisun Vural; Gizem Kaplan
Journal:  Int Ophthalmol       Date:  2021-07-08       Impact factor: 2.031

2.  Association Between Sex Hormones and Visual Field Progression in Women With Primary Open Angle Glaucoma: A Cross-Sectional and Prospective Cohort Study.

Authors:  Yichao Qiu; Jian Yu; Li Tang; Jun Ren; Mingxi Shao; Shengjie Li; Yunxiao Song; Wenjun Cao; Xinghuai Sun
Journal:  Front Aging Neurosci       Date:  2021-12-24       Impact factor: 5.750

3.  Relationship between Androgen Deprivation Therapy and Normal-Tension Glaucoma in Patients with Prostate Cancer: A Nationwide Cohort Study.

Authors:  Jee Soo Ha; Hye Sun Lee; Ju-Young Park; Jinhyung Jeon; Do Kyung Kim; Min Kim; Ho Sik Hwang; Tae Hyo Kim; Hyun Kyu Ahn; Kang Su Cho
Journal:  Yonsei Med J       Date:  2022-10       Impact factor: 3.052

4.  Androgen deprivation therapy may reduce the risk of primary open-angle glaucoma in patients with prostate cancer: a nationwide population-based cohort study.

Authors:  Hyun Kyu Ahn; Hye Sun Lee; Ju-Young Park; Do Kyung Kim; Min Kim; Ho Sik Hwang; Jong Won Kim; Jee Soo Ha; Kang Su Cho
Journal:  Prostate Int       Date:  2021-05-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.